Vertex stock price target lowered to $405 by RBC on pain franchise setbacks

Published 05/08/2025, 17:48
Vertex stock price target lowered to $405 by RBC on pain franchise setbacks

Investing.com - RBC Capital lowered its price target on Vertex Pharmaceuticals (NASDAQ:VRTX) to $405.00 from $430.00 on Tuesday, while maintaining a Sector Perform rating on the stock. The biotech giant, currently valued at $101 billion, is trading near its 52-week low of $377.85, with a high EBITDA multiple of 24.16x.

The price target reduction follows setbacks to Vertex’s pain franchise, including a limited chronic pain regulatory path and disappointing efficacy results for the company’s next-generation Nav1.8 ’993 therapy.

RBC Capital noted these developments will likely dampen market enthusiasm about Vertex’s ability to capture broader pain revenue opportunities, especially as the stock trades at a premium 24x multiple.

The investment firm estimates that Vertex’s pain franchise was receiving more than $25 billion in valuation, suggesting significant implications from these setbacks for the company’s overall market position.

Despite the challenges, RBC acknowledged that Vertex’s cystic fibrosis franchise continues to provide a "solid backbone with compelling margins, competitive positioning, and IP," though noted that launches of Alyftrek, Journavx, and Casgevy are unlikely to significantly impact financial results in the near term.

In other recent news, Vertex Pharmaceuticals reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $4.52 compared to the forecasted $4.27. The company also exceeded revenue projections, reporting $2.96 billion against the anticipated $2.91 billion. These results highlight the company’s strong financial performance for the quarter. Additionally, Cantor Fitzgerald adjusted its price target for Vertex Pharmaceuticals to $485 from $535, maintaining an Overweight rating. This revision comes after disappointing clinical data from Vertex’s VX-993 bunionectomy trials and negative regulatory feedback on a potential broad peripheral neuropathic pain label for suzetrigine. Despite these setbacks, the Overweight rating suggests continued confidence in the company’s long-term potential. These developments provide investors with a mix of positive earnings results and challenges in Vertex’s clinical strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.